NCT05243550 2026-05-11ENVISIONUroGen Pharma Ltd.Phase 3 Active not recruiting240 enrolled 20 charts 1 FDA
NCT06774131 2026-04-29A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerUroGen Pharma Ltd.Phase 3 Recruiting70 enrolled